Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study

SIMPLE SUMMARY: Ramucirumab has been shown to be effective as a second-line agent after sorafenib in hepatocellular carcinoma (HCC) patients whose α-fetoprotein was ≥400 ng/mL. We performed a retrospective cohort study to investigate ramucirumab efficacy in a real-world setting. Progression-free sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasui, Yutaka, Kurosaki, Masayuki, Tsuchiya, Kaoru, Hayakawa, Yuka, Hasebe, Chitomi, Abe, Masami, Ogawa, Chikara, Joko, Kouji, Ochi, Hironori, Tada, Toshifumi, Nakamura, Shinichiro, Furuta, Koichiro, Kimura, Hiroyuki, Tsuji, Keiji, Kojima, Yuji, Akahane, Takehiro, Tamada, Takashi, Uchida, Yasushi, Kondo, Masahiko, Mitsuda, Akeri, Izumi, Namiki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221496/
https://www.ncbi.nlm.nih.gov/pubmed/35740647
http://dx.doi.org/10.3390/cancers14122975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221496/
https://www.ncbi.nlm.nih.gov/pubmed/35740647
http://dx.doi.org/10.3390/cancers14122975

Ejemplares similares